Pharmacokinetics of doxorubicin after intratumoral injection using a thermosensitive hydrogel in tumor-bearing mice

Journal of Controlled Release

Volumn 142, Issue 1, 2010, Pages 101-107

  Al Abd, Ahmed M ^a   Hong, Ki Yun ^b   Song, Soo Chang ^b   Kuh, Hyo Jeong ^a  

^a The Catholic University of Korea   (South Korea)

^b Korea Institute of Science and Technology   (South Korea)

Author keywords

Doxorubicin; Drug delivery system; Pharmacokinetics; Poly(organophosphazene); Solid tumors

Indexed keywords

ANTI-CANCER AGENTS; ANTITUMOR EFFECT; AQUEOUS SOLUTIONS; BODY TEMPERATURE; CARDIAC TOXICITY; CYTOTOXIC DRUGS; DOXORUBICIN; DRUG DELIVERY SYSTEM; GASTRIC TUMORS; IN-VITRO; INTRATUMORAL INJECTION; SOLID TUMORS; THERMO-SENSITIVE HYDROGEL;

BIOCOMPATIBILITY; DRUG DELIVERY; ONCOLOGY; PHARMACOKINETICS; TOXICITY; TUMORS;

HYDROGELS;

DOXORUBICIN; ISOLEUCINE; MACROGOL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; AQUEOUS SOLUTION; AREA UNDER THE CURVE; ARTICLE; ASCITES; BIOCOMPATIBILITY; BODY TEMPERATURE; CARDIOTOXICITY; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DEATH; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG HALF LIFE; DRUG RETENTION; DRUG SAFETY; DRUG TUMOR LEVEL; FEMALE; HEAT SENSITIVITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; HYDROGEL; IN VITRO STUDY; IN VIVO STUDY; MAXIMUM PLASMA CONCENTRATION; MORTALITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; STOMACH CANCER; SUSTAINED RELEASE FORMULATION; TUMOR VOLUME; TUMOR XENOGRAFT;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CELL LINE, TUMOR; DELAYED-ACTION PREPARATIONS; DOXORUBICIN; HUMANS; HYDROGEL; INJECTIONS; MICE; ORGANOPHOSPHORUS COMPOUNDS; POLYMERS; STOMACH NEOPLASMS; TEMPERATURE;

EID: 76749141882     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2009.10.003     Document Type: Article

References (35)

1. Hortobagyi G.N. Anthracyclines in the treatment of cancer. An overview. Drugs 1997, 54(Suppl. 4):1-7.
2. Lee H.S., Son C.B., Shin S.H., Kim Y.S. Clinical correlation between brain natriutetic peptide and anthracyclin-induced cardiac toxicity. Cancer Res. Treat. 2008, 40(3):121-126.
3. Licata S., Saponiero A., Mordente A., Minotti G. Doxorubicin metabolism and toxicity in human myocardium: role of cytoplasmic deglycosidation and carbonyl reduction. Chem. Res. Toxicol. 2000, 13(5):414-420.
4. Bagalkot V., Farokhzad O.C., Langer R., Jon S. An aptamer-doxorubicin physical conjugate as a novel targeted drug-delivery platform. Angew. Chem. Int. Ed. Engl. 2006, 45(48):8149-8152.
5. Weinberg B.D., Ai H., Blanco E., Anderson J.M., Gao J. Antitumor efficacy and local distribution of doxorubicin via intratumoral delivery from polymer millirods. J. Biomed. Mater. Res. A 2007, 81(1):161-170.
6. Gao Z.G., Lee D.H., Kim D.I., Bae Y.H. Doxorubicin loaded pH-sensitive micelle targeting acidic extracellular pH of human ovarian A2780 tumor in mice. J. Drug Target. 2005, 13(7):391-397.
7. Wang X., Wang Y., Chen Z., Shin D.M. Advances of cancer therapy by nanotechnology. Cancer Res. Treat. 2009, 41(1):1-11.
8. Muggia F.M., Hainsworth J.D., Jeffers S., Miller P., Groshen S., Tan M., Roman L., Uziely B., Muderspach L., Garcia A., Burnett A., Greco F.A., Morrow C.P., Paradiso L.J., Liang L.J. Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation. J. Clin. Oncol. 1997, 15(3):987-993.
9. Duncan R. Designing polymer conjugates as lysosomotropic nanomedicines. Biochem. Soc. Trans. 2007, 35(pt 1):56-60.
10. Westphal M., Hilt D.C., Bortey E., Delavault P., Olivares R., Warnke P.C., Whittle I.R., Jaaskelainen J., Ram Z. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro Oncol. 2003, 5(2):79-88.
11. Kakinoki S., Taguchi T., Saito H., Tanaka J., Tateishi T. Injectable in situ forming drug delivery system for cancer chemotherapy using a novel tissue adhesive: characterization and in vitro evaluation. Eur. J. Pharm. Biopharm. 2007, 66(3):383-390.
12. Packhaeuser C.B., Schnieders J., Oster C.G., Kissel T. In situ forming parenteral drug delivery systems: an overview. Eur. J. Pharm. Biopharm. 2004, 58(2):445-455.
13. Ortiz R., Au J.L., Lu Z., Gan Y., Wientjes M.G. Biodegradable intraprostatic doxorubicin implants. AAPS J. 2007, 9(2):E241-E250.
14. Chen G., Hoffman A.S. Graft copolymers that exhibit temperature-induced phase transitions over a wide range of pH. Nature 1995, 373(6509):49-52.
15. Bhattarai N., Matsen F.A., Zhang M. PEG-grafted chitosan as an injectable thermoreversible hydrogel. Macromol. Biosci. 2005, 5(2):107-111.
16. Ruel-Gariepy E., Leroux J.C. In situ-forming hydrogels-review of temperature-sensitive systems. Eur. J. Pharm. Biopharm. 2004, 58(2):409-426.
17. Amiji M.M., Lai P.K., Shenoy D.B., Rao M. Intratumoral administration of paclitaxel in an in situ gelling poloxamer 407 formulation. Pharm. Dev. Technol. 2002, 7(2):195-202.
18. Ruel-Gariepy E., Shive M., Bichara A., Berrada M., Le Garrec D., Chenite A., Leroux J.C. A thermosensitive chitosan-based hydrogel for the local delivery of paclitaxel. Eur. J. Pharm. Biopharm. 2004, 57(1):53-63.
19. Jeong B., Bae Y.H., Lee D.S., Kim S.W. Biodegradable block copolymers as injectable drug-delivery systems. Nature 1997, 388(6645):860-862.
20. Crommen J.H., Schacht E.H., Mense E.H. Biodegradable polymers. I. Synthesis of hydrolysis-sensitive poly[(organo)phosphazenes]. Biomaterials 1992, 13(8):511-520.
21. Kang G.D., Cheon S.H., Song S.C. Controlled release of doxorubicin from thermosensitive poly(organophosphazene) hydrogels. Int. J. Pharm. 2006, 319(1-2):29-36.
22. Chun C., Lee S.M., Kim S.Y., Yang H.K., Song S.C. Thermosensitive poly(organophosphazene)-paclitaxel conjugate gels for antitumor applications. Biomaterials 2009, 30(12):2349-2360.
23. Crommen J.H., Schacht E.H., Mense E.H. Biodegradable polymers. II. Degradation characteristics of hydrolysis-sensitive poly[(organo)phosphazenes]. Biomaterials 1992, 13(9):601-611.
24. Kang G.D., Cheon S.H., Khang G., Song S.C. Thermosensitive poly(organophosphazene) hydrogels for a controlled drug delivery. Eur. J. Pharm. Biopharm. 2006, 63(3):340-346.
25. Al-Abd A.M., Kim N.H., Song S.C., Lee S.J., Kuh H.J. A simple HPLC method for doxorubicin in plasma and tissue of nude mice. Arch. Pharm. Res. 2009, 32(4):605-611.
26. Bhattarai N., Ramay H.R., Gunn J., Matsen F.A., Zhang M. PEG-grafted chitosan as an injectable thermosensitive hydrogel for sustained protein release. J. Control. Release 2005, 103(3):609-624.
27. Lu W.L., Qi X.R., Zhang Q., Li R.Y., Wang G.L., Zhang R.J., Wei S.L. A pegylated liposomal platform: pharmacokinetics, pharmacodynamics, and toxicity in mice using doxorubicin as a model drug. J. Pharmacol. Sci. 2004, 95(3):381-389.
28. Lammers T., Peschke P., Kuhnlein R., Subr V., Ulbrich K., Huber P., Hennink W., Storm G. Effect of intratumoral injection on the biodistribution and the therapeutic potential of HPMA copolymer-based drug delivery systems. Neoplasia 2006, 8(10):788-795.
29. Han H.D., Lee A., Hwang T., Song C.K., Seong H., Hyun J., Shin B.C. Enhanced circulation time and antitumor activity of doxorubicin by comblike polymer-incorporated liposomes. J. Control. Release 2007, 120(3):161-168.
30. Zheng J.H., Chen C.T., Au J.L., Wientjes M.G. Time- and concentration-dependent penetration of doxorubicin in prostate tumors. AAPS PharmSci 2001, 3(2):E15.
31. Kataoka K., Matsumoto T., Yokoyama M., Okano T., Sakurai Y., Fukushima S., Okamoto K., Kwon G.S. Doxorubicin-loaded poly(ethylene glycol)-poly(beta-benzyl-L-aspartate) copolymer micelles: their pharmaceutical characteristics and biological significance. J. Control. Release 2000, 64(1-3):143-153.
32. Bibby D.C., Talmadge J.E., Dalal M.K., Kurz S.G., Chytil K.M., Barry S.E., Shand D.G., Steiert M. Pharmacokinetics and biodistribution of RGD-targeted doxorubicin-loaded nanoparticles in tumor-bearing mice. Int. J. Pharm. 2005, 293(1-2):281-290.
33. Arai T., Joki T., Akiyama M., Agawa M., Mori Y., Yoshioka H., Abe T. Novel drug delivery system using thermoreversible gelation polymer for malignant glioma. J. Neurooncol. 2006, 77(1):9-15.
34. Kakinoki S., Taguchi T. Antitumor effect of an injectable in-situ forming drug delivery system composed of a novel tissue adhesive containing doxorubicin hydrochloride. Eur. J. Pharm. Biopharm. 2007, 67(3):676-681.
35. Tang N., Du G., Wang N., Liu C., Hang H., Liang W. Improving penetration in tumors with nanoassemblies of phospholipids and doxorubicin. J. Natl. Cancer Inst. 2007, 99(13):1004-1015.